<DOC>
	<DOC>NCT01467349</DOC>
	<brief_summary>This will be a retrospective analysis of efficacy, safety and tolerability of raltegravir as part of an optimized therapy in a clinical setting. Follow-up is calculated from the treatment initiation (with or without raltegravir) up to the date of discontinuation of the considered regimen or the date of last visit or the date of lost to follow-up, whichever came first. The Aim of the study is to evaluate the efficacy and safety of raltegravir-containing regimens in a urban clinic setting.</brief_summary>
	<brief_title>Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>raltegravir-containing regimens</keyword>
	<keyword>HIV urban clinic setting</keyword>
</DOC>